SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes

SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes

Using levels of neutralizing antibodies (nAbs), we evaluate the successful Chilean SARS-CoV-2 vaccine campaign, which combines different vaccine technologies and heterologous boosters. From a population-based study performed in November 2021, we randomly selected 120 seropositive individuals, organi...

Full description

Bibliographic Details
Main Authors:	Aguilera, X. (Author), Apablaza, M. (Author), Castillo-Laborde, C. (Author), Cortes, L.J (Author), González, C. (Author), Hormazábal, J. (Author), Icaza, G. (Author), Nuñez-Franz, L. (Author), Pérez, C. (Author), Quezada-Gate, R. (Author), Ramírez-Riffo, C. (Author), Ramírez-Santana, M. (Author), Rubilar, P. (Author), Said, M. (Author), Vial, C. (Author), Vial, P. (Author)
Format:	Article
Language:	English
Published:	MDPI 2022
Subjects:	AZD1222 BNT162b2 CoronaVac COVID-19 cross-sectional design neutralizing antibodies SARS-CoV-2 vaccine-preventable diseases vaccines viruses
Online Access:	View Fulltext in Publisher

Similar Items

Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers
by: Yu-Mi Wi, et al.
Published: (2021-08-01)

Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors
by: Evangelos Terpos, et al.
Published: (2021-05-01)

Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222
by: Thomas Perkmann, et al.
Published: (2021-09-01)

Cardiovascular Adverse Events Reported from COVID-19 Vaccines: A Study Based on WHO Database
by: Jeet Kaur R, et al.
Published: (2021-07-01)

Acute prolonged motor aura resembling ischemic stroke after COVID − 19 vaccination (CoronaVac): the first case report
by: Wanakorn Rattanawong, et al.
Published: (2021-08-01)

Transient visual field loss after COVID-19 vaccination: Experienced by ophthalmologist, case report
by: Chaisiri Jumroendararasame, et al.
Published: (2021-12-01)

Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine
by: Luisa F. Duarte, et al.
Published: (2021-09-01)

Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report
by: Ekachai Singhatiraj, et al.
Published: (2021-09-01)

Antibodies against Receptor Binding Domain of SARS-CoV-2 spike protein induced by BNT162b2 vaccine: results from a pragmatic, real-life study
by: Marcello Mariani, et al.
Published: (2021-10-01)

SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals
by: Andrea Lombardi, et al.
Published: (2021-08-01)

Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey
by: Abanoub Riad, et al.
Published: (2021-06-01)

Effectiveness of BNT162b2 COVID-19 Vaccine in Preventing Severe Symptomatic Infection among Healthcare Workers
by: Efrén Murillo-Zamora, et al.
Published: (2021-07-01)

A novel adverse effect of the BNT162b2 mRNA vaccine: First episode of acute mania with psychotic features
by: Umit Haluk Yesilkaya, et al.
Published: (2021-12-01)

Polymyalgia rheumatica as uncommon adverse event following immunization with COVID‐19 vaccine: A case report and review of literature
by: Ciro Manzo, et al.
Published: (2021-09-01)

Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection
by: Anna Patrignani, MD, et al.
Published: (2021-11-01)

Occurrence of BNT162b2 Vaccine Adverse Reactions Is Associated with Enhanced SARS-CoV-2 IgG Antibody Response
by: Yoav Rechavi, et al.
Published: (2021-09-01)

Anterior uveitis onset after bnt162b2 vaccination: is this just a coincidence?
by: Giulia Renisi, et al.
Published: (2021-09-01)

Impact of Full Vaccination with mRNA BNT162b2 on SARS-CoV-2 Infection: Genomic and Subgenomic Viral RNAs Detection in Nasopharyngeal Swab and Saliva of Health Care Workers
by: Michela Deiana, et al.
Published: (2021-08-01)

Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2
by: Jean-Louis Bayart, et al.
Published: (2021-06-01)

Neutralizing Antibodies Titers and Side Effects in Response to BNT162b2 Vaccine in Healthcare Workers with and without Prior SARS-CoV-2 Infection
by: José Javier Morales-Núñez, et al.
Published: (2021-07-01)

Delayed large pruritic eruption to the BNT162b2 mRNA vaccine
by: Takeshi Terashima
Published: (2021-01-01)

Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine
by: Annalisa Ciabattini, et al.
Published: (2021-09-01)

Vaccin mot SARS-CoV-2 – en utvärdering av effektivitet och säkerhet av ledande vaccin : En Litteraturstudie
by: Wrywood, Sean
Published: (2021)

Facial and Oral Manifestations Following COVID-19 Vaccination: A Survey-Based Study and a First Perspective
by: Marta Mazur, et al.
Published: (2021-05-01)

Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
by: Hiroaki Akiyama, et al.
Published: (2021-01-01)

Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers
by: Louise Benning, et al.
Published: (2021-08-01)

Antibody Response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2
by: Marcello Salvaggio, et al.
Published: (2021-09-01)

Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals
by: Daniel Lozano-Ojalvo, et al.
Published: (2021-08-01)

The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
by: Ahmed Zaqout, et al.
Published: (2021-07-01)

Acute myocarditis following administration of BNT162b2 vaccine
by: Mhd Baraa Habib, et al.
Published: (2021-01-01)

COVID-19 vaccine in the Kingdom of Saudi Arabia: A true operation warp speed
by: Mazin Barry, et al.
Published: (2021-01-01)

Robust Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the First Dose in Previously Infected Individuals and After the Second Dose in Uninfected Individuals
by: Yosuke Hirotsu, et al.
Published: (2021-08-01)

The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients
by: Emanuel Zitt, et al.
Published: (2021-06-01)

Outbreak of infections with the COVID-19 virus mutation B.1.351 about four weeks after the second successful vaccination with BNT162b2
by: Ortloff, Andrea, et al.
Published: (2021-04-01)

Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
by: Giovanna Cocomazzi, et al.
Published: (2021-08-01)

Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study
by: Alessio, N., et al.
Published: (2022)

From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape
by: Chiranjib Chakraborty, et al.
Published: (2021-07-01)

Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination
by: Brent Appelman, et al.
Published: (2021-10-01)

Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection
by: Nick K Jones, et al.
Published: (2021-04-01)

Age- and Sex-Graded Data Evaluation of Vaccination Reactions after Initial Injection of the BNT162b2 mRNA Vaccine in a Local Vaccination Center in Germany
by: Manuela A. Hoffmann, et al.
Published: (2021-08-01)